Letters “Breakthrough” drug in Alzheimer’s disease

Need for a trial of solanezumab in mild Alzheimer’s disease

BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h4441 (Published 01 September 2015) Cite this as: BMJ 2015;351:h4441
  1. David Torgerson, director1
  1. 1York Trials Unit, University of York, York, UK
  1. david.torgerson{at}york.ac.uk

McCartney is right to be cautious about the effectiveness of solanezumab in Alzheimer’s disease, which she says might be a chance finding.1 But this is not because of the relatively small size of the trial but the nature of testing subgroups within an overall …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe